Moderna is going to ask regulators to approve its combination vaccine against COVID-19 and influenza, the company said on June 30.
The company said a phase 3 study evaluating its influenza vaccine candidate, mRNA-1010—which utilizes the same messenger ribonucleic acid (mRNA) platform as its COVID-19 vaccine—showed positive effectiveness.
In the trial, which featured 40,805 participants and compared mRNA-1010 to an existing seasonal flu vaccine in adults aged 50 and up, the relative protection from the candidate was 26.6 percent better. In a subgroup analysis among participants aged at least 65, the relative efficacy was 27.4 percent.
“Today’s strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults,” Stéphane Bancel, Moderna’s CEO, said in a statement….